{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "1915"
        },
        "variant_string_id": "LRRK2 I1915T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in LRRK2 cause Parkinson's disease (PD) via age-dependent dopaminergic neuron degeneration. LRRK2 antagonizes miRNAs (let-7 and miR-184*) to dysregulate E2F1/DP synthesis, a key event in pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism: LRRK2 gain-of-function mutations disrupt miRNA-mediated repression of E2F1/DP, leading to neuronal toxicity and PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "An EGFP reporter with let-7-binding sites in the 3′UTR (EGFP-let-7-3′UTR) was used to monitor miRNA activity. Pathogenic LRRK2 variants (I1915T, G2019S) increased reporter expression, while wild-type LRRK2 and dLRRK RNAi decreased it.",
          "judgment": "Yes",
          "reasoning": "The miRNA reporter assay directly models the disease mechanism (miRNA pathway impairment). The assay is standard for studying miRNA function and has been validated in prior studies.",
          "decision": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate specific assay controls and replicates (3a)",
          "extracted_paper_info": "Pathogenic variants (I1915T, G2019S) and wild-type LRRK2 were compared. RNAi for dLRRK was used as a loss-of-function control. Results were consistent across Da-Gal4 and TH-Gal4 drivers.",
          "judgment": "No",
          "reasoning": "The abstract does not explicitly state the number of replicates or statistical tests. While controls exist, replicates are not documented.",
          "decision": "Proceed to Step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/validated assay",
          "extracted_paper_info": "The EGFP-let-7-3′UTR reporter assay is a standard method for studying miRNA function and has been widely used in prior studies.",
          "judgment": "Yes",
          "reasoning": "The assay is broadly accepted and validated in the field, even without explicit replication details in this study.",
          "decision": "Functional evidence strength is Max PS3_supporting"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation (4b)",
          "extracted_paper_info": "Two control variants (I1915T, G2019S) and wild-type LRRK2 were tested. RNAi for dLRRK was used as a loss-of-function control.",
          "judgment": "Total controls: 3 (I1915T, G2019S, wild-type, RNAi). Total < 10.",
          "reasoning": "Fewer than 10 control variants were tested, so the strength remains PS3_supporting.",
          "decision": "Final strength: PS3_supporting"
        }
      ]
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in LRRK2 cause Parkinson's disease (PD) via age-dependent dopaminergic neuron degeneration. LRRK2 antagonizes miRNAs (let-7 and miR-184*) to dysregulate E2F1/DP synthesis, a key event in pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism: LRRK2 gain-of-function mutations disrupt miRNA-mediated repression of E2F1/DP, leading to neuronal toxicity and PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "An EGFP reporter with let-7-binding sites in the 3′UTR (EGFP-let-7-3′UTR) was used to monitor miRNA activity. Pathogenic LRRK2 variants (I1915T, G2019S) increased reporter expression, while wild-type LRRK2 and dLRRK RNAi decreased it.",
          "judgment": "Yes",
          "reasoning": "The miRNA reporter assay directly models the disease mechanism (miRNA pathway impairment). The assay is standard for studying miRNA function and has been validated in prior studies.",
          "decision": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate specific assay controls and replicates (3a)",
          "extracted_paper_info": "Pathogenic variants (I1915T, G2019S) and wild-type LRRK2 were compared. RNAi for dLRRK was used as a loss-of-function control. Results were consistent across Da-Gal4 and TH-Gal4 drivers.",
          "judgment": "No",
          "reasoning": "The abstract does not explicitly state the number of replicates or statistical tests. While controls exist, replicates are not documented.",
          "decision": "Proceed to Step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/validated assay",
          "extracted_paper_info": "The EGFP-let-7-3′UTR reporter assay is a standard method for studying miRNA function and has been widely used in prior studies.",
          "judgment": "Yes",
          "reasoning": "The assay is broadly accepted and validated in the field, even without explicit replication details in this study.",
          "decision": "Functional evidence strength is Max PS3_supporting"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation (4b)",
          "extracted_paper_info": "Two control variants (I1915T, G2019S) and wild-type LRRK2 were tested. RNAi for dLRRK was used as a loss-of-function control.",
          "judgment": "Total controls: 3 (I1915T, G2019S, wild-type, RNAi). Total < 10.",
          "reasoning": "Fewer than 10 control variants were tested, so the strength remains PS3_supporting.",
          "decision": "Final strength: PS3_supporting"
        }
      ]
    }
  ]
}